PARP1 and breast carcinoma: Since PARP-1 inhibitors result in synthetic lethal effects, specifically in BRCA-mutated cells, MDA-MB-436 (BRCA-1-mutated breast cancer cell line) was selected to conduct a cell proliferation assay for the analogs that exhibited the most active inhibition effect against the PARP-1 enzyme.